Page 22 - TD-4-3

Tumor Discovery FBXW7 in Leukemia

87. Veneziani I, Fruci D, Compagnone M, Pistoia V, doi: 10.1038/s41420-023-01494-y
Rossi P, Cifaldi L. The BET-bromodomain inhibitor JQ1
renders neuroblastoma cells more resistant to NK cell- 97. Zanganeh S, Zahedi AM, Sattarzadeh Bardsiri M, et al. Recent
mediated recognition and killing by downregulating advances and applications of the CRISPR-Cas system in the
gene therapy of blood disorders. Gene. 2024;931:148865.
ligands for NKG2D and DNAM-1 receptors. Oncotarget.
2019;10(22):2151-2160. doi: 10.1016/j.gene.2024.148865
doi: 10.18632/oncotarget.26736 98. Hesham HM, Dokla EME, Elrazaz EZ, Lasheen DS, Abou
El Ella DA. FLT3-PROTACs for combating AML resistance:
88. Fiskus W, Piel J, Collins M, et al. BRG1/BRM inhibitor
targets AML stem cells and exerts superior preclinical Analytical overview on chimeric agents developed,
efficacy combined with BET or menin inhibitor. Blood. challenges, and future perspectives. Eur J Med Chem.
2024;143(20):2059-2072. 2024;277:116717.
doi: 10.1182/blood.2023022832 doi: 10.1016/j.ejmech.2024.116717
89. Cao L, Ruiz Buendia GA, Fournier N, et al. Resistance 99. Wu M, Zhao Y, Zhang C, Pu K. Advancing proteolysis
mechanism to Notch inhibition and combination therapy targeting chimera (PROTAC) nanotechnology in protein
in human T-cell acute lymphoblastic leukemia. Blood Adv. homeostasis reprograming for disease treatment. ACS
2023;7(20):6240-6252. Nano. 2024;18(42):28502-28530.
doi: 10.1182/bloodadvances.2023010380 doi: 10.1021/acsnano.4c09800
90. Chang YS, Gills JJ, Kawabata S, et al. Inhibition of the 100. Stephenson SEM, Costain G, Blok LER, et al. Germline
NOTCH and mTOR pathways by nelfinavir as a novel variants in tumor suppressor FBXW7 lead to impaired
treatment for T cell acute lymphoblastic leukemia. Int J ubiquitination and a neurodevelopmental syndrome. Am J
Oncol. 2023;63(5):128. Hum Genet. 2022;109(4):601-617.
doi: 10.3892/ijo.2023.5576 doi: 10.1016/j.ajhg.2022.03.002
91. Sabol HM, Ferrari AJ, Adhikari M, et al. Targeting notch 101. Zhang Q, Mady ASA, Ma Y, et al. The WD40 domain
inhibitors to the myeloma bone marrow niche decreases of FBXW7 is a poly(ADP-ribose)-binding domain that
tumor growth and bone destruction without gut toxicity. mediates the early DNA damage response. Nucleic Acids Res.
Cancer Res. 2021;81(19):5102-5114. 2019;47(8):4039-4053.
doi: 10.1158/0008-5472.CAN-21-0524 doi: 10.1093/nar/gkz058
92. Inuzuka H, Fukushima H, Shaik S, Liu P, Lau AW, Wei W. Mcl-1 102. Duan Y, Liu Z, Wang Q, et al. Targeting MYC:
ubiquitination and destruction. Oncotarget. 2011;2(3):239-244. Multidimensional regulation and therapeutic strategies in
doi: 10.18632/oncotarget.242 oncology. Genes Dis. 2025;12(4):101435.
93. Sneyers F, Kerkhofs M, Speelman-Rooms F, et al. Intracellular doi: 10.1016/j.gendis.2024.101435
BAPTA directly inhibits PFKFB3, thereby impeding 103. Zhang X, Bian H, Wei W, et al. DLX5 promotes osteosarcoma
mTORC1-driven Mcl-1 translation and killing MCL-1- progression via activation of the NOTCH signaling pathway.
addicted cancer cells. Cell Death Dis. 2023;14(9):600. Am J Cancer Res. 2021;11(6):3354-3374.
doi: 10.1038/s41419-023-06120-4 104. Yao W, Bai L, Wang S, Zhai Y, Sun SY. Mcl-1 levels critically
94. Pan Y, Liu J, Gao Y, et al. FBXW7 loss of function promotes impact the sensitivities of human colorectal cancer cells
esophageal squamous cell carcinoma progression via to APG-1252-M1, a novel Bcl-2/Bcl-X(L) dual inhibitor
elevating MAP4 and ERK phosphorylation. J Exp Clin that induces Bax-dependent apoptosis. Neoplasia.
Cancer Res. 2023;42(1):75. 2022;29:100798.
doi: 10.1186/s13046-023-02630-3 doi: 10.1016/j.neo.2022.100798
95. Xia H, Dufour CR, Medkour Y, et al. Hepatocyte FBXW7- 105. Yu S, Stappenbelt C, Chen M, et al. Cyclin E1 overexpression
dependent activity of nutrient-sensing nuclear receptors triggers interferon signaling and is associated with
controls systemic energy homeostasis and NASH antitumor immunity in breast cancer. J Immunother Cancer.
progression in male mice. Nat Commun. 2023;14(1):6982. 2025;13(3):e009239.
doi: 10.1038/s41467-023-42785-3 doi: 10.1136/jitc-2024-009239
96. Chan DKH, Mandal A, Hester S, et al. Biallelic FBXW7 106. Welcker M, Orian A, Jin J, et al. The Fbw7 tumor suppressor
knockout induces AKAP8-mediated DNA damage regulates glycogen synthase kinase 3 phosphorylation-
in neighbouring wildtype cells. Cell Death Discov. dependent c-Myc protein degradation. Proc Natl Acad Sci U
2023;9(1):200. S A. 2004;101(24):9085-9090.

Volume 4 Issue 3 (2025) 14 doi: 10.36922/TD025150027